I. Amendments to the Claims:

This listing of claims replaces without prejudice all prior versions, and listings, of claims in the application:

Listing of claims:

1. (Currently amended) A method of inhibiting secretion of vascular endothelial growth factor in an animal in need of such inhibition, comprising administering to the animal an effective amount of a compound of Formula I, or a salt, ~~solvate, or hydrate~~ thereof:



I

wherein

R^1 and R^2 are each independently selected from H, OH, $C_{1\text{-}6}$alkyl, $C_{1\text{-}6}$alkoxy, NH_2, NH-$C_{1\text{-}6}$alkyl, N($C_{1\text{-}6}$alkyl)($C_{1\text{-}6}$alkyl), SH, S-$C_{1\text{-}6}$alkyl, O-Si($C_{1\text{-}6}$alkyl)($C_{1\text{-}6}$alkyl)($C_{1\text{-}6}$alkyl), NO_2, CF_3, OCF_3 and halo;

R^3 is selected from H, OH, $C_{1\text{-}6}$alkyl, $C_{1\text{-}6}$alkoxy, NH_2, NH-$C_{1\text{-}6}$alkyl, N($C_{1\text{-}6}$alkyl)($C_{1\text{-}6}$alkyl), SH, S-$C_{1\text{-}6}$alkyl, O-Si($C_{1\text{-}6}$alkyl)($C_{1\text{-}6}$alkyl)($C_{1\text{-}6}$alkyl), NO_2, halo and CH_2-S-$(CH_2)_n$ Ar;

R^4 is selected from C(X)R^5, SO_3Ar, NH_2, NH-$C_{1\text{-}6}$alkyl, N($C_{1\text{-}6}$alkyl)($C_{1\text{-}6}$alkyl), P(O)$(OH)_2$, P(O)$(OC_{1\text{-}6}alkyl)_2$, and C(NH_2)=C$(CN)_2$;

X is selected from O,S, NH and N-$C_{1\text{-}6}$alkyl;

R^5 is selected from NH_2, OH, NH$(CH_2)_p$Ar, NH$(CH_2)_p$OH, $(CH_2)_p OC_{1\text{-}6}$alkyl, $C_{1\text{-}6}$alkyl, $C_{1\text{-}6}$alkoxy, $NHNH_2$, NHC(O)NH_2, NHC(O)$C_{1\text{-}6}$alkoxy, N-morpholino and N-pyrrolidino; and

Ar is an aromatic or heteroaromatic group, unsubstituted or substituted with 1-4 substituents, independently selected from OH, $C_{1\text{-}6}$alkyl, $C_{1\text{-}6}$alkoxy, NH_2, NH-$C_{1\text{-}6}$alkyl, N($C_{1\text{-}6}$alkyl)($C_{1\text{-}6}$alkyl), SH, S-$C_{1\text{-}6}$alkyl, NO_2, CF_3, OCF_3 and halo;

n is 0 to 4; and

p is 1-4.

2. (Cancelled)

3. (Cancelled)

4. (Currently amended) A method of inhibiting an effect of vascular endothelial growth factor in an animal in need of such inhibition, comprising administering to the animal an effective amount of a compound of Formula I, or a salt, ~~solvate, or hydrate~~ thereof:



I

wherein

R^1 and R^2 are each independently selected from H, OH, $C_{1\text{-}6}$alkyl, $C_{1\text{-}6}$alkoxy, NH_2, NH-$C_{1\text{-}6}$alkyl, N($C_{1\text{-}6}$alkyl)($C_{1\text{-}6}$alkyl), SH, S-$C_{1\text{-}6}$alkyl, O-Si($C_{1\text{-}6}$alkyl)($C_{1\text{-}6}$alkyl)($C_{1\text{-}6}$alkyl), NO_2, CF_3, OCF_3 and halo;

R^3 is selected from H, OH, $C_{1\text{-}6}$alkyl, $C_{1\text{-}6}$alkoxy, NH_2, NH-$C_{1\text{-}6}$alkyl, N($C_{1\text{-}6}$alkyl)($C_{1\text{-}6}$alkyl), SH, S-$C_{1\text{-}6}$alkyl, O-Si($C_{1\text{-}6}$alkyl)($C_{1\text{-}6}$alkyl)($C_{1\text{-}6}$alkyl), NO_2, halo and CH_2-S-$(CH_2)_n$Ar;

R^4 is selected from $C(X)R^5$, SO_2Ar, NH_2, NH-$C_{1\text{-}6}$alkyl, N($C_{1\text{-}6}$alkyl)($C_{1\text{-}6}$alkyl), $P(O)(OH)_2$, $P(O)(OC_{1\text{-}6}alkyl)_2$, and $C(NH_2)=C(CN)_2$;

X is selected from O,S, NH and N-$C_{1\text{-}6}$alkyl;

R^5 is selected from NH_2, OH, $NH(CH_2)_pAr$, $NH(CH_2)_pOH$, $(CH_2)_pOC_{1\text{-}6}$alkyl, $C_{1\text{-}6}$alkyl, $C_{1\text{-}6}$alkoxy, $NHNH_2$, $NHC(O)NH_2$, NHC(O)$C_{1\text{-}6}$alkoxy, N-morpholino and N-pyrrolidino; and

Ar is an aromatic or heteroaromatic group, unsubstituted or substituted with 1-4 substituents, independently selected from OH, $C_{1\text{-}6}$alkyl, $C_{1\text{-}6}$alkoxy, NH_2, NH-$C_{1\text{-}6}$alkyl, N($C_{1\text{-}6}$alkyl)($C_{1\text{-}6}$alkyl), SH, S-$C_{1\text{-}6}$alkyl, NO_2, CF_3, OCF_3 and halo;

n is 0 to 4; and

p is 1-4.

5. (Cancelled)

6. (Cancelled)

7. (Previously amended) The method of claim 4, wherein the effect of vascular endothelial growth factor is angiogenesis, vasculogenesis, arteriogenesis, vascular permeability or inflammation.

8-57. (Cancelled)

58. (Currently Amended) The method of claim ~~57~~ 1, further comprising administering to said animal a therapeutically effective amount of at least a second anti-cancer agent.

59. (Original) The method of claim 58, wherein said at least a second anti-cancer agent is a chemotherapeutic agent, radiotherapeutic agent, anti-angiogenic agent, apoptosis-inducing agent or anti-tubulin drug or a tumor-targeted chemotherapeutic agent, radiotherapeutic agent, anti-angiogenic agent, apoptosis-inducing agent or anti-tubulin drug.

60. (Original) The method of claim 59, wherein said at least a second anti-cancer agent is an anti tubulin drug selected from the group consisting of colchicine, taxol, vinblastine, vincristine, vindescine and a combretastatin or a tumor-targeted anti-tubulin drug selected from the group consisting of colchicine, taxol, vinblastine, vincristine, vindescine and a combretastatin.

61-69. (Cancelled)